- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01048281
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
November 21, 2023 updated by: Stanford University
Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood samples from upper gastrointestinal cancer patients and persons at high inherited risk for these cancers.
We hope to learn the role genes and proteins play in the development of gastric and esophageal cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Meredith Mills
- Phone Number: (650) 724-5223
- Email: bluett@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University School of Medicine
-
Sub-Investigator:
- Hanlee P. Ji
-
Sub-Investigator:
- Vandana Bhardwaj Sharma
-
Contact:
- Meredith Mills
- Phone Number: 650-724-5223
- Email: bluett@stanford.edu
-
Principal Investigator:
- James M Ford
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adults with gastric or esophageal cancer
Description
Inclusion Criteria:
- Over 18
- Diagnosed with gastric or esophageal cancer OR at an increased hereditary risk for upper GI cancer
Exclusion Criteria:
- Under 18
- No family or personal history of gastric or esophageal cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
p53 activity by routine pathologic analysis
Time Frame: time of collection
|
time of collection
|
NER activity by routine pathologic analysis
Time Frame: time of collection
|
time of collection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: James M Ford, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2002
Primary Completion (Estimated)
January 1, 2099
Study Completion (Estimated)
January 1, 2099
Study Registration Dates
First Submitted
January 11, 2010
First Submitted That Met QC Criteria
January 12, 2010
First Posted (Estimated)
January 13, 2010
Study Record Updates
Last Update Posted (Actual)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 21, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIUPR0001
- 76274 (Other Identifier: Stanford University Alternate IRB Approval Number)
- CA109190 (Other Identifier: NIH)
- SU-11022007-787 (Other Identifier: Stanford University)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Cancer
-
Jeeyun LeeRecruitingStomach Cancer, AdenocarcinomaKorea, Republic of
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
Ohio State University Comprehensive Cancer CenterPharmacia and UpjohnCompletedStomach Cancer | Esophageal Cancer | Cancer of Stomach | Esophagus CancerUnited States
-
BayerCompletedPrevention of Oesophagus Cancer and Stomach CancerUnited Kingdom
-
Chinese University of Hong KongRecruiting
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Genentech, Inc.; SCRI Development Innovations... and other collaboratorsCompletedStomach Cancer | Gastric Cancer | Esophageal CancerUnited States
-
MacroGenicsMerck Sharp & Dohme LLCCompletedStomach Cancer | Gastric Cancer | Esophageal CancerKorea, Republic of, United States, Taiwan, Singapore, Canada
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Genentech, Inc.; Brigham and Women's HospitalCompletedStomach Cancer | Esophageal CancerUnited States
Clinical Trials on Blood draw
-
Abbott Point of CareNot yet recruitingPrecision of Potassium (K) Test in Capillary Whole Blood
-
University Hospital, Strasbourg, FranceNot yet recruitingKidney Transplantation | Humoral Rejection | Kidney Allograft Biopsy | Microvascular Inflammation
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCCompletedMelanomaUnited States
-
Turtle Health, Inc.Completed
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
National Heart Centre SingaporeDuke-NUS Graduate Medical SchoolRecruiting
-
Duke UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingHematologic MalignancyUnited States
-
University of BonnRecruitingSARS-CoV 2 | COVIDGermany
-
Joseph M. Still Research Foundation, Inc.RecruitingInflammatory Response | Deep Vein Thrombosis | Multi Organ Failure | Nosocomial InfectionUnited States